Stock Details
BMY is Bristol-Myers Squibb Company's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 71.83$. Average daily volumn in 3 months 9.69M. Market cap 152.05B



Stock symbol : BMY. Exchange : NYSE. Currency : USD
Lastest price : 71.21$. Total volume : 10.18M. Market state PREPRE
Click reload if you want to check the lastest price on market!!!

Bristol-Myers Squibb Company (BMY)
Last Price
71.21$
Change
0.68
Volume
10.18M

Previous Close70.53
Open70.63
Day Range70.10-71.91
Bid0.00 x 800
Ask0.00 x 900
Volume10.18M
Average Volume9.69M
Market Cap152.05B
Beta0.42
52 Week Range53.22-80.59
Trailing P/E23.66
Foward P/E8.89
Dividend (Yield %)3.04%
Ex-Dividend Date2022-10-06



Financial Details


According to Bristol-Myers Squibb Company's financial reports the company's revenue in 2021 were 46.38B an increase( +9.52%) over the years 2020 revenue that were of 42.52B. In 2021 the company's total earnings were 6.99B while total earnings in 2020 were -9.02B(-166.67%).


Loading ...



Organization

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indi... cations; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Market Cap:
152.05B
Revenue:
46.38B
Total Assets:
109.31B
Total Cash:
13.98B


News about "Bristol-Myers Squibb Company"

should-investors-buy-bristol-myers-squibb-stock-image

Should Investors Buy Bristol Myers Squibb Stock?

Source from : YAHOO!Finance - 1 days ago

BMY's YTD performance indicates the stock has been a viable hedge against inflation because people can ill afford to cut back on health-focused spending.See details»


with-78-institutional-ownership-bristol-myers-squibb-company-nysebmy-is-a-favorite-amongst-the-big-guns-image

With 78% institutional ownership, Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst the big guns

Source from : YAHOO!Finance - 3 days ago

If you want to know who really controls Bristol-Myers Squibb Company ( NYSE:BMY ), then you'll have to look at ...See details»


bristol-myers-squibb-a-gem-in-a-period-of-macroeconomic-uncertainties-image

Bristol-Myers Squibb: A Gem In A Period Of Macroeconomic Uncertainties

Source from : Seeking Alpha - 3 days ago

The company's medicines received over 10 regulatory approvals in Europe, Japan, and the US in the first half of 2022. Read more to see our price target on BMY.See details»


what-bristol-myers-squibb-companys-nysebmy-roe-can-tell-us-image

What Bristol-Myers Squibb Company's (NYSE:BMY) ROE Can Tell Us

Source from : Nasdaq - 13 days ago

We'll use ROE to examine Bristol-Myers Squibb Company (NYSE:BMY), by way of a worked example. Return on equity or ROE is a key measure used to assess how efficiently a company's management is ...See details»


Bristol-Myers Squibb Company (BMY) distance from 20-day Simple moving Average is 1.02%: What to Expect?

Source from : investchronicle - 1 days ago

At the end of the latest market close, Bristol-Myers Squibb Company (BMY) was valued at $71.71. In that particular session, Stock kicked-off at the price of $71.78 while reaching the peak value of $72 ...See details»


SyntheX and Bristol Myers Squibb Enter Into a Research Collaboration to Discover and Develop Targeted Protein Degradation (TPD) Therapeutics

Source from : Business Insider - 1 days ago

Collaboration will leverage SyntheX's proprietary ToRNeDO molecular glue discovery platform to discover small molecule degraders against targets ...See details»


Autolus Therapeutics Shares Jump After Cancer-Collaboration Agreement with Bristol Myers

Source from : MarketWatch - 1 days ago

By Sabela Ojea Shares of Autolus Therapeutics Ltd. on Tuesday rose 14% after the U.K. leukemia drug maker announced the signing of collaboration ...See details»


Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?

Source from : Nasdaq - 8 days ago

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...See details»


bristol-myers-squibb-nysebmy-receives-buy-rating-from-the-goldman-sachs-group-image

Bristol-Myers Squibb (NYSE:BMY) Receives Buy Rating from The Goldman Sachs Group

Source from : Defense World - 7 days ago

The Goldman Sachs Group restated their buy rating on shares of Bristol-Myers Squibb (NYSE:BMY โ€“ Get Rating) in a research report report published on Tuesday, MarketBeat reports. They currently have a ...See details»


with-78-ownership-bristol-myers-squibb-company-nysebmy-boasts-of-strong-institutional-backing-image

With 78% ownership, Bristol-Myers Squibb Company (NYSE:BMY) boasts of strong institutional backing

Source from : Yahoo Finance - 7 days ago

A look at the shareholders of Bristol-Myers Squibb Company ( NYSE:BMY ) can tell us which group is most powerful.See details»


bristol-myers-squibb-plots-wirral-expansion-image

Bristol Myers Squibb plots Wirral expansion

Source from : Place North West - 23 hours ago

The pharmaceutical company has submitted a planning application to build a 37,000 sq ft R&D facility at its 11-acre Moreton complex.See details»


psoriatic-arthritis-market-to-surpass-us-190139-million-by-2028-bristol-myers-squibb-company-abbvie-inc-pfizer-inc-amgen-inc-image

Psoriatic Arthritis Market to Surpass US$ 19,013.9 Million by 2028 | Bristol-Myers Squibb Company, AbbVie Inc, Pfizer, Inc, Amgen, Inc.

Source from : Medgadget - 8 days ago

For example, in September 2015, AstraZeneca, a MNC drugstore and biotech organization declared that they came into a partnership alliance with Valeant drugstore International, Inc. an MNC ...See details»


Bristol-Myers Squibb, Cash, Cheniere Energy And This Tech Company Are CNBC's Final Trades

Source from : Benzinga.com on MSN - 11 days ago

On CNBCโ€™s โ€œHalftime Report Final Trades,โ€ Jim Lebenthal of Cerity Partners said Bristol-Myers Squibb Co (NYSE: BMY) has a โ€œgood dividend yieldโ€ and is a &l ...See details»


Bristol Myers Squibb hosts conference call for investors

Source from : Business Insider - 4 days ago

The company, Bristol Myers Squibb, is set to host investors and clients on a conference call on 10/26/2022 11:48:01 PM. The call comes after the company's earnings, which are set to be announced ...See details»